These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35255355)

  • 21. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
    Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
    Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression patterns of immune checkpoints in acute myeloid leukemia.
    Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
    J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese.
    Huang X; Liu X; Ye Y; Zhang T; Mei S; Zhu T; Peng S; Cai J; Yan Z; Zeng K; Nie D; Sun L; Hou X; Zhao J
    Front Immunol; 2021; 12():607966. PubMed ID: 33717091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.
    Elashi AA; Sasidharan Nair V; Taha RZ; Shaath H; Elkord E
    Oncoimmunology; 2019; 8(2):e1542918. PubMed ID: 30713804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
    Huang RY; Francois A; McGray AR; Miliotto A; Odunsi K
    Oncoimmunology; 2017; 6(1):e1249561. PubMed ID: 28197366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls.
    Lushnikova A; Bohr J; Wickbom A; Münch A; Sjöberg K; Hultgren O; Wirén A; Hultgren Hörnquist E
    Front Med (Lausanne); 2021; 8():727412. PubMed ID: 34722568
    [No Abstract]   [Full Text] [Related]  

  • 32. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
    Marcq E; Siozopoulou V; De Waele J; van Audenaerde J; Zwaenepoel K; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits EL
    Oncoimmunology; 2017; 6(1):e1261241. PubMed ID: 28197385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
    Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
    Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.
    Schlößer HA; Drebber U; Kloth M; Thelen M; Rothschild SI; Haase S; Garcia-Marquez M; Wennhold K; Berlth F; Urbanski A; Alakus H; Schauss A; Shimabukuro-Vornhagen A; Theurich S; Warnecke-Ebertz U; Stippel DL; Zippelius A; Büttner R; Hallek M; Hölscher AH; Zander T; Mönig SP; von Bergwelt-Baildon M
    Oncoimmunology; 2016 May; 5(5):e1100789. PubMed ID: 27467911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
    Marcq E; Waele J; Audenaerde JV; Lion E; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits ELJ
    Oncotarget; 2017 Oct; 8(52):89722-89735. PubMed ID: 29163783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
    Buckle I; Guillerey C
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
    Christodoulou MI; Zaravinos A
    Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4
    Gorchs L; Fernández Moro C; Bankhead P; Kern KP; Sadeak I; Meng Q; Rangelova E; Kaipe H
    Front Immunol; 2019; 10():847. PubMed ID: 31068935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.